Prolonged isolated thrombocytopenia (PT) is a serious complication of allogeneic haematopoietic stem cell transplantation (allo-HSCT). Murine studies and in vitro experiments suggest that mesenchymal stem cells (MSCs) can, not only to support haematopoiesis, but also preferentially support megakaryocytopoiesis in bone marrow (BM). However, little is known about the quantity and function of BM MSCs in PT patients. In a case-control study, we found that BM MSCs from PT patients exhibited significantly reduced proliferative capacities, increased reactive oxygen species and senescence. Antioxidant (N-acetyl-L-cysteine, NAC) treatment in vitro not only quantitatively and functionally improved BM MSCs derived from PT patients through down-regulation of the p38 (also termed MAPK14) and p53 (also termed TP53) pathways but also partially rescued the impaired ability of BM MSCs to support megakaryocytopoiesis. Subsequently, a pilot study showed that the overall response of NAC treatment was obtained in 7 of the enrolled PT patients (N = 10) without significant side effects. Taken together, the results indicated that dysfunctional BM MSCs played a role in the pathogenesis of PT and the impaired BM MSCs could be improved by NAC in vitro. Although requiring further validation, our data indicate that NAC might be a potential therapeutic approach for PT patients after allo-HSCT.
transfusions for more than 60 days after allogeneic haematopoietic stem cell transplantation (allo-HSCT) (Kim et al, 2006; Song et al, 2017) , is a frequent complication and associated with higher transplant-related mortality and reduced overall survival after allo-HSCT (Zhang et al, 2011) . Several risk factors, including stem cell source, doses of infused CD34 + cells, donor-specific anti-human lecocyte antigen antibodies, conditioning intensity, cytomegalovirus (CMV) serostatus and graft-versus-host disease (GvHD), have been associated with PT after allo-HSCT (Anasetti et al, 1989; Verdonck et al, 1991; Chang et al, 2009 Chang et al, , 2015 Nakamae et al, 2011; Zhang et al, 2011) . Nevertheless, the underlying mechanisms remain poorly understood, and the available treatment options for PT are limited (First et al, 1985; Yamazaki et al, 2006) . Platelet production is a consecutive process in the bone marrow (BM) microenvironment (De Botton et al, 2002; Reems et al, 2010) . Optimal thrombocytopoiesis requires adequate interactions of various cytokines with target cell populations and BM microenvironment (Han et al, 1991) . Many cell types, including osteoblasts, endothelial cells, mesenchymal stem cells (MSCs) and various mature immune cells, contribute to BM microenvironment (Riether et al, 2015) . Our group reported that endothelial cells were significantly reduced in the BM microenvironment of PT patients (Kong et al, 2014) . Additionally, we recently found dysregulated T cell responses in the BM microenvironment of PT patients (Zhang et al, 2015a; Song et al, 2017) . Together, these data indicate that the impaired BM microenvironment might contribute to the occurrence of PT.
Bone marrow-derived MSCs (BM MSCs) are multipotent adult stem cells that possess the capacity to differentiate into several cellular elements of the BM microenvironment to support haematopoiesis and regulate immunological responses (Dazzi et al, 2006; Gebler et al, 2012) . Moreover, emerging evidence from in vitro and murine studies suggests that the cross-talk between megakaryocytes and MSCs in the BM microenvironment regulates megakaryocyte maturation and thrombopoiesis (Cheng et al, 2000; Angelopoulou et al, 2003) . However, less is known about the quantity and functional roles of BM MSCs in PT patients following allo-HSCT. Moreover, what drives the dysfunction of BM MSCs and its molecular mechanisms remain to be elucidated in PT patients.
Reactive oxygen species (ROS) are free radicals derived from diatomic oxygen and exhibit diverse reactivities in many cell types. In the case of MSCs, ROS are involved in signalling, proliferation and differentiation (Meagher et al, 1988; Carriere et al, 2003) . Intracellular ROS accumulation appears to be the major cause of human MSCs senescence and is related to the apoptosis of MSCs (Ebert et al, 2006; Heo et al, 2009; Wei et al, 2010) . N-acetyl-L-cysteine (NAC), acting both as a precursor of reduced glutathione and a direct ROS scavenger, has been widely used as an exogenous antioxidant in many ex vivo experiments (Shi et al, 2014) and is clinically used in respiratory diseases (Rushworth & Megson, 2014) . Nevertheless, no previous studies have focused on the roles of ROS in regulating the dysfunction and repairing BM MSCs in PT patients.
In the current prospective case-control study, we evaluated whether the number and function of BM MSCs in allo-HSCT recipients with PT differed from those with good graft function (GGF) and healthy donors (HD). Furthermore, we investigated whether aberrant levels of ROS in BM MSCs played a role in the pathogenesis of PT after allo-HSCT, as well as its underlying molecular mechanisms. Subsequently, a pilot study was performed to evaluate the efficacy and safety of NAC in PT patients.
Methods

Patients and controls
In the prospective case-control study, transplant recipients were identified from the cohort who received an allotransplant between 1 January 2016 and 30 June 2017 at Peking University Institute of Haematology. A total of 83 patients who developed PT were eligible for in vitro BM MSC culture. Thirty-two matched transplant recipients with GGF were selected from the same cohort after matching for age, pretransplant disease state, and post-transplant interval ("riskset sampling") (Wacholder et al, 1992) . After 3 weeks of in vitro BM culture using MSC medium, 25 of the 83 PT patients and 25 of the 32 GGF patients had produced adherent layers.
Bone marrow samples from transplant HD (N = 20) were normal controls. The normal cohort comprised 10 males and 10 females, aged 18-60 years. The study was approved by the Ethics Committee of Peking University People's Hospital, and written informed consent was obtained from all subjects, including PT patients, GGF patients and HD, in compliance with the Declaration of Helsinki.
Clinical assessment of the pilot study Ten of the above 25 PT patients were enrolled in a pilot cohort study to evaluate the efficacy and safety of oral NAC treatment (400 mg three times a day). Patients who were receiving other maintenance regimens, primarily corticosteroids or thrombopoietin, were also eligible if the dose of treatment had been stable in the past month and the dose was expected to remain unchanged at least until initial response was evaluated.
The primary end points of the cohort study included complete response, response, overall response and no response. Secondary end point was adverse events (safety). The treatment responses were evaluated weekly after the interventions. The treatment responses were defined as the following platelet counts for 7 consecutive days without transfusion support: (i) "Complete response" was defined as a platelet count of at least 100 9 10 9 /l; (ii) "Response" was defined as a platelet count between 50 and 100 9 10 9 /l; (iii) "Overall response"
included "complete response" and "response"; and (iv) "No response" was defined as a platelet count lower than 50 9 10 9 /l (Tanaka et al, 2016; Elalfy et al, 2017) .
Definitions of PT and GGF
Prolonged isolated thrombocytopenia was defined as the engraftment of all peripheral blood cell lines (absolute neutrophil count >0Á5 9 10 9 /l for 3 consecutive days and haemoglobin >70 g/l without transfusion support) other than a platelet count <20 9 10 9 /l or dependence on platelet transfusions for more than 60 days after allo-HSCT in the presence of complete donor chimerism (Kim et al, 2006; Song et al, 2017) . GGF was defined as persistent successful engraftment beyond 28 days after HSCT (Kong et al, 2013 (Kong et al, , 2014 (Kong et al, , 2016a Shi et al, 2016; Song et al, 2017) . Patients with evidence of poor graft function, severe GvHD, or haematological relapse within 60 days after allo-HSCT were excluded (Kong et al, 2013 (Kong et al, , 2016a Shi et al, 2016) .
Transplantation protocols
Donor selection, human leucocyte antigen (HLA) typing, stem cell harvesting, conditioning therapy, and GvHD prophylaxis were conducted as previously described (Huang et al, 2012; Wang et al, 2014a,b) . The grafts were recombinant human granulocyte colony-stimulating factormobilized peripheral blood stem cells and BM stem cells from HLA-matched or HLA-mismatched sibling donors in PT or GGF patients.
BM MSC culture
Bone marrow mononuclear cells (BMMNCs) were isolated by density gradient centrifugation using lymphocyte separation medium (HaoYang, Tianjin, China). BMMNCs were resuspended in MSC medium consisting of Dulbecco's modified Eagle medium (DMEM) with 10% fetal bovine serum (FBS) (Gibco, Grand Island, NY). BMMNCs were seeded into 6-well plates at a concentration of up to 5 9 10 6 /well cells for primary culture (Klaus et al, 2010; Hamzic et al, 2015) . Non-adherent cells were removed on the fourth day and adherent cells fed weekly with MSC medium until reaching approximately 80% confluence, when they were re-seeded into passage 1. Subsequent passages 2-4 were generated in the same way until reaching confluence. All experiments were carried out using BM MSCs derived from passages 2-4. The number of PT patients and their matched GGF patients included in the independent experiments are shown in the figures. Cell images were obtained under a light microscope in a blinded fashion by two investigators. Three fields were randomly analysed for comparison.
Immunophenotyping of BM MSCs
To characterize the typical MSC phenotype, the BM adherent cells of passage 3 were analysed for the expression of CD34, CD45, CD73, CD90, CD105, CD14, HLA-DR (BioLegend, San Diego, CA) and Nestin (R&D Systems, Minneapolis, MN) by flow cytometry. Aliquots of unstained samples were used as negative controls. Data were analysed using BD LSRFortessa software (Becton Dickinson Biosciences, San Jose, CA).
BM MSC differentiation assays
Trypsinized BM MSCs from passage 3 were induced for adipogenic and osteogenic differentiation. Adipogenic differentiation was induced following a 21-day culture of cells in AdipoDiff media (Miltenyi, Bergisch Gladbach, Germany), and adipogenesis was assessed by Oil Red O staining. Osteogenic differentiation was induced following a 14-day culture of cells in OsteoDiff media (Miltenyi), and osteogenesis was assessed by alkaline phosphatase (ALP) staining (Roche, Indianapolis, USA). Two investigators evaluated samples in a blinded fashion. Three fields were randomly analysed for comparison.
Fibroblast colony-forming units (CFU-F) assay
Bone marrow mononuclear cells were seeded at 1 9 10 5 /ml in duplicate wells of 6 cm dishes with DMEM supplemented with 10% FBS for 14 days. Colonies were stained using Wright's Giemsa staining.
Cell proliferation assay
Cell proliferation was measured using a cell counting kit-8 (CCK-8) (Dojindo, Kumamoto, Japan) assay according to the manufacturer's instructions. Generally, cells were seeded into 96-well cell culture cluster plates at a concentration of 2 9 10 3 cells per well in volumes of 100 ml and grown overnight. CCK-8 reagents were added to a subset of wells and incubated for 2 h at 37°C. The final absorbance of each well was determined at 450 nm using a micro-plate reader (BioRad, Foster City, CA, USA). Cell proliferation was also detected after 48 h treatment with 1 mM NAC (Sigma, St. Louis, MO) (Song et al, 2010; Li et al, 2014; Kong et al, 2016a; Shi et al, 2016) , 10 lmol/l p38 (also termed MAPK14) inhibitor (SB203580, Sigma) (Zhang et al, 2015b; Shi et al, 2016) , or 10 lmol/l p53 (also termed TP53) inhibitor (PFT-a, Sigma) (Bragado et al, 2007; Zhang et al, 2016) .
Senescence and apoptosis analysis assay
Bone marrow MSCs were passaged into 6-well culture plates at a density of 2 9 10 4 cells per well. After 24 h, senescence- 
Measurement of intracellular levels of ROS and proteins
Reactive oxygen species staining was performed using an ROS staining kit (Beyotime, Shanghai, China) according to the manufacturer's protocol. To detect the levels of intracellular proteins, cells were fixed, permeabilized and incubated with phospho-Histone H2A.X-PE, phospho-p53-PE, p53-Alexa Fluor 488, p21-Alexa Fluor 647 and phospho-p38 MAPK-Alexa Fluor 647 (Cell Signaling Technology).
Western blot analysis
Cells were harvested and lysed in radioimmunoprecipitation assay buffer containing proteinase inhibitor and PhosSTOP (Roche) on ice for 30 min. Proteins were separated by sodium dodecyl sulphate polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride (Millipore, Bedford, USA) membranes. The membranes were then blocked with 5% BSA at room temperature for 2 h and incubated overnight with antibodies against phospho-p38, total p38, phospho-p53, total p53, p21 (also termed CDKN1A), phospho-JNK, total JNK, phospho-ERK and total ERK, phospho-Akt, total Akt and Actin (Cell Signaling Technology). Horseradish peroxidase-conjugated secondary antibody was used in conjunction with an ECL chemiluminescence detection system (Pierce, Biotechnology Inc., Rockford, USA).
Colony-forming unit (CFU) assays
CD34
+ cells were isolated from the BMMNCs of HD, GGF and PT patients with using a CD34 MicroBead Kit (Miltenyi). CFUs were assayed using MethoCult TM H4434 Classic (Stem Cell Technologies, Vancouver, BC, Canada) as previously described (Shi et al, 2016) . Cultures were assayed in duplicate, and the results are expressed as the mean AE SEM.
Histological analysis of BM microenvironment
Bone marrow trephine biopsies were obtained from the posterior superior iliac spine, fixed with 4% paraformaldehyde for 1 h, dehydrated with 70% ethanol, embedded in paraffin, and cut into 5-mm thick sections. Haematoxylin and eosin (H-E) staining was performed on each tissue section. Megakaryocytes were identified as large cells with blue/grey cytoplasm, which often contained large, multilobed nuclei. Megakaryocytes were quantified as the number per high-power field (hpf). Each H-E stained section was examined by light microscopy (Axiovert 200; Carl Zeiss, Jena, Germany).
Coculture of BM CD34 + progenitor cells with BM MSCs
Bone marrow MSCs (2 9 10 4 /ml) from PT patients and GGF patients were plated in 6-well plates and then treated with mitomycin-C (Sigma) to prevent cell overgrowth (Hatami et al, 2015) for 24 h. Then, isolated CD34 + cells from HD were resuspended at 3 9 10 5 cells/ml with Stemspan medium (Stem Cell Technologies) containing 100 ng/ ml stem cell factor, 100 ng/ml thrombopoietin and 10 ng/ml interleukin 3 (PeproTech, Locky Hill, NJ, USA). After 7 days of coculture, colony-forming unit megakaryocytes (CFU-MKs) were quantitated using a commercially available kit (MegaCult-C; Stem Cell Technologies) according to the manufacturer's instructions. A total of 5 9 10 4 CD34 + cells were plated in each chamber slide for 12 days and megakaryocyte colonies were defined as groups of 3 or more glycoprotein IIb/IIIa-positive cells.
To measure ploidy distribution after 12 days of coculture, the megakaryocytes were identified by labelling with CD41a and incubating with 500 ll propidium iodide (PI, BD Biosciences PharMingen).
The platelets produced were detected as previously described (Yang et al, 2010) . After incubation with CD41a, each sample was diluted to 200 ll and collected at a high rate for 60 s by flow cytometry.
Statistical analysis
Statistical analyses were performed using one-way analysis of variance (ANOVA) for comparisons among the groups. Subject variables were compared using the chi-square test for categorical variables and the Mann-Whitney U test for continuous variables. Wilcoxon's test for paired data was used to identify the drug effects. Analyses were performed using GraphPad Prism 6.0 (GraphPad Software, La Jolla, CA, USA), and P-values <0Á05 were considered statistically significance. Data on small numbers are presented without P-values (Hills, 2017) .
Results
Patient characteristics
As shown in Table I , a total of 25 PT patients and 25 matched GGF patients after allo-HSCT, whose BM samples produced MSCs within 3 weeks of in vitro culture, were analysed for the number and function of BM MSCs. BM MSCs of PT patients and GGF patients were evaluated at similar intervals after allo-HSCT (median, 61 days vs. 62 days, P = 0Á87) to minimize the potential influence of the interval after allo-HSCT.
The transplanted CD34 + cell dose, pre-transplantation cycles of chemotherapy, conditioning and history of GvHD, were comparable between patients with PT and GGF. However, a higher proportion of PT patients had a history of CMV infection shortly after allo-HSCT (P = 0Á03).
Growth and passaging capacity of BM MSCs
Bone marrow samples from 83 PT patients, 32 GGF patients and 20 HD were assessed for stromal layer formation. Cultures from all HD BM samples produced confluent layers of adherent cells composed of spindle-shaped cells. Fifty-eight of the 83 BM samples from PT patients and 7 of the 32 BM samples from GGF patients failed to produce any adherent layers within 3 weeks of culture ( Fig 1A) . In addition, the time necessary for confluent layer formation at passage 0 was significantly longer for BM MSCs from patients with PT compared with GGF and HD (Fig 1B; 26 days vs. 16 days vs. 13 days; P = 0Á0001).
Characterization of BM MSCs
After 3 passages of cultivation, BM MSC layers were assessed using light microscopy and showed the characteristic fibroblastoid appearance of BM MSCs from GGF patients and HD, whereas BM MSCs from PT patients were larger and flattened ( Fig 1C) .
To further confirm the presence of MSCs in the adherent BM stromal layers, we assessed adherent cells from PT patients, GGF patients and HD at passage 3. The typical BM MSC phenotype was confirmed by positive expression of CD73, CD90, CD105 and Nestin and negative expression of haematopoietic antigens, including CD34, CD45, CD14 and HLA-DR in the adherent stromal layers by flow cytometry (Fig 2A) . aGvHD, acute GvHD; ALL, acute lymphocytic leukaemia; AML, acute myeloid leukaemia; ANC, absolute neutrophil count; ATG, antithymocyte globulin; BM, bone marrow; BU, busulphan; CMV, cytomegalovirus; CY, cyclophosphamide; GGF, good graft function; GvHD, graft-versus-host disease; Hb, haemoglobin; HLA, human leucocyte antigen; hpf, high power field; HSCT, haematopoietic stem cell transplantation; PLT, platelet; PT, prolonged isolated thrombocytopenia; WBC, white blood cell count. *Group matching criteria included age at HSCT (AE1 years), pre-HSCT cycles of chemotherapy (AE1cycle), disease status at HSCT and BM microenvironment evaluated time after HSCT (AE5 days). For each case, one GGF control was randomly selected from the same cohort at which the PT occurred ("risk-set sampling"). †The continuous variables were compared using the Mann-Whitney U-test, and the differences in frequency between the 2 groups were compared using the chi-square test. The criterion for statistical significance was P < 0Á05.
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Adipocytic and osteoblastic differentiation assays were performed for further characterization of MSCs. BM MSCs derived from PT patients displayed defective differentiation into osteoblasts and adipocytes in vitro after inductive conditions compared to those from GGF patients and HD (Fig 2B,C) .
Impaired growth kinetics and increased cellular senescence of BM MSCs from PT patients
To assess the clonogenic potential of BM MSCs derived from PT patients, GGF patients and HD, we performed CFU-F assays. CFU-F counts of PT patients were significantly reduced compared with GGF patients and HD (Fig 3A,B; 4Á1 AE 0Á8 vs. 16Á0 AE 1Á0 vs. 17Á9 AE 1Á0; P < 0Á0001). BM MSCs from PT patients showed a lower proliferative capacity than those from GGF patients and HD, as demonstrated by CCK-8 assays (Fig 3C) .
Consistent with these findings, BM MSCs from PT patients were more prone to cellular senescence, as shown by a significantly higher number of SAb-gal-positive cells compared to those from GGF patients (Fig 3D,E; 30Á1 AE 4Á4% vs. 10Á6 AE 1Á9%; P = 0Á0007). As shown in Fig 3F , the apoptosis rate of BM MSCs from PT patients was higher than that in GGF patients (5Á1 AE 2Á0% vs. 3Á6 AE 2Á3%; P = 0Á07), but this was not statistically significant. Moreover, the expression of c-H2AX-positive DNA double-strand breaks was significantly higher in BM MSCs from PT patients than in those from GGF patients (Fig 3G; 2770 AE 246Á6 vs. 1704 AE 162Á6; P = 0Á0017). These data indicate that the DNA double-strand breaks and senescence might represent a mechanism responsible for the impaired growth of BM MSCs observed in PT patients.
Levels of ROS, phospho-p38 and phospho-p53 were elevated in BM MSCs from PT patients
To explore the underlying mechanism of dysfunctional BM MSCs in PT patients, we examined the basal levels of ROS in BM MSCs by flow cytometry. The levels of intracellular ROS in BM MSCs from PT patients were significantly higher than those from GGF patients (Fig 4A; 1911 AE 170Á3 vs. 1277 AE 144Á6; P = 0Á005). Moreover, positive correlations were observed between the levels of ROS and the percentages of senescent cells in BM MSCs (Fig 4B; Pearson r = 0Á36 [95% CI 0Á08, 0Á59]; P = 0Á01; N = 45). Positive correlations were observed between the ROS levels and the percentage of senescent cell levels in BM MSCs. Flow cytometry revealed increased phospho-p38 (C), phospho-p53 (D) and p21 (E), whereas no significant differences in phospho-Akt (F), phospho-JNK (G), phospho-ERK (H) expression were observed in BM MSCs from PT patients, GGF patients and HD. Data are expressed as the MFI (mean AE SEM). (I) Representative western blots of phospho-p38, total p38, phospho-p53, total p53, p21, phospho-Akt, total Akt, phospho-JNK, total JNK, phospho-ERK, total ERK and Actin in BM MSCs from PT patients, GGF patients and HD. P-values <0Á05 were considered statistically significant. GGF, good graft function; HD, healthy donor; MFI, mean fluorescence intensity; PT, prolonged isolated thrombocytopenia; ROS, reactive oxygen species. [Colour figure can be viewed at wileyonlinelibrary.com] Next, we examined the basal levels of phospho-p38, phospho-p53, p21, phospho-ERK, phospho-JNK, and phosphoAkt in BM MSCs derived from PT patients, GGF patients and HD using flow cytometry. Substantially higher levels of phospho-p38 (Fig 4C; 2072 AE 256Á2 vs. 990Á3 AE 114Á8; P = 0Á0005), phospho-p53 (Fig 4D; 1784 AE 155Á8 vs. 1046 AE 74Á1; P = 0Á0007), and p21 (Fig 4E; 2107 AE 267Á5 vs. 1341 AE 118Á3; P = 0Á04) were detected in BM MSCs from PT patients compared to those from GGF patients. In contrast, intracellular levels of phospho-Akt (Fig 4F; 2687 AE 238Á5 vs. 2862 AE 509Á2; P = 0Á68), phospho-JNK (Fig 4G; 2475 AE 361Á3 vs. 2009 AE 261Á7; P = 0Á45), and phospho-ERK (Fig 4H; 4921 AE 596Á6 vs. 4596 AE 567Á4; P = 0Á80) were not significantly different between patients with PT and GGF. The expression patterns of these intracellular proteins were further validated by Western blot (Fig 4I) .
NAC improved the number and function of BM MSCs in PT patients through the p38 and p53 pathways
After 48-h treatment, antioxidant NAC (1 mmol/l) significantly decreased the intracellular ROS levels of BM MSCs in PT patients (Fig 5A; 2047 AE 222Á6 vs. 1470 AE 155Á3; P = 0Á002). Moreover, the intracellular levels of phospho-p38 (Fig 5B; 2544 AE 309Á6 vs. 1809 AE 334Á3; P = 0Á001) and phospho-p53 (Fig 5C; 2606 AE 465Á7 vs. 1980 AE 338Á7; P = 0Á002) were significantly decreased in BM MSCs of PT patients after NAC treatment (Fig 5D) . NAC increased the number (Fig 5E; 1Á40 AE 0Á09-fold; P = 0Á004) and proliferation rate (Fig 5F; 0Á30 AE 0Á04 vs. 0Á43 AE 0Á04; P = 0Á02) in BM MSCs of PT patients compared with those in untreated controls. Moreover, NAC reduced the percentage of SAb-galpositive cells in BM MSCs of PT patients compared with those in untreated control (Fig 5G; 27Á3 AE 5Á2% vs. 13Á6 AE 2Á3%; P = 0Á004).
Because elevated intracellular phospho-p38 and phosphop53 levels were demonstrated in the BM MSCs from PT patients, we next evaluated the effects on the number and function of cultivated BM MSCs from PT patients by inhibiting p38 and p53 using p38 inhibitors (SB203580) or p53 inhibitors (PFT-a), respectively. In vitro treatment with SB203580 significantly increased the number (Fig 5E; 1Á40 AE 0Á14-fold; P = 0Á02) and proliferation rate (Fig 5F; 0Á30 AE 0Á04 vs. 0Á37 AE 0Á05; P = 0Á002) of BM MSCs in PT patients. Both SB203580 and PFT-a attenuated the percentage of senescent cells (Fig 5G; 27Á3 AE 5Á2% vs. 17Á0 AE 3Á8% vs. 19Á9 AE 3Á7%; P = 0Á004). NAC produced superior effects on the number and function of BM MSCs from PT patients than SB203580 and PFT-a.
BM MSCs from PT patients have a diminished megakaryocyte maturation supporting capacity
In situ histological analyses of the BM trephine biopsies were performed to characterize the number of megakaryocytes in patients after allo-HSCT and HD. As illustrated in Fig 6A, the number of megakaryocytes was significantly decreased in the PT group compared with the GGF group (2 per hpf vs. 5 per hpf, P < 0Á0001).
Colony-forming unit assays were performed to detect the multipotential differentiation ability of BM CD34 + cells from PT patients. As shown in Fig 6B, the BM CD34 + cells from PT patients had similar plating efficiencies for erythroid CFU, erythroid burst-forming units, and granulocytemacrophage CFU compared with those in GGF patients. However, BM CD34 + cells from PT patients had a deficit in mixed lineage CFU (CFU-GEMM) outgrowth compared with GGF patients (Fig 6B; 0Á2 AE 0Á2 vs. 2Á4 AE 0Á5; P = 0Á02). We performed a coculture experiment to determine the supportive capacity of BM MSCs from PT patients and GGF patients. After CD34 + cells from HD were cocultured on PTderived MSCs for 7 days, CFU-MKs counts were lower in the PT-MSCs group (Fig 6C,D; 49Á3 AE 6Á4 vs. 73Á7 AE 8Á7; P = 0Á02). The percentages of megakaryocytes (Fig 6E; 16Á8 AE 3Á3% vs. 24Á8 AE 1Á9%; P = 0Á02) and mature megakaryocytes (N ≥ 4) (Fig 6F; 7Á8 AE 2Á5% vs. 16Á2 AE 2Á1%; P = 0Á002) were significantly lower in CD34 + cells cocultured on PT-MSCs compared to those observed on GGF-MSCs. The platelet release values in the GGF-MSC group were higher than in the PT-MSC group (Fig 6G; 970Á7 AE 209Á3 vs. 2015 AE 277Á1; P = 0Á006). Megakaryocyte apoptosis in the GGF-MSC group was higher than that in the PT-MSCs group, but this did not reach statistical significance (Fig 6H; 8Á0 AE 1Á2% vs. 7Á0 AE 0Á9%; P = 0Á67).
NAC improved megakaryocytopoiesis in BM CD34
+ cells cocultured with MSCs from PT patients
To determine whether NAC could improve the ability of impaired BM MSCs to support megakaryocytopoiesis in vitro, we cocultured BM CD34 + cells from HD with BM
MSCs from PT patients with or without 48-h NAC treatment. NAC exposure improved the ability of BM MSCs from PT patients to support megakaryocytopoiesis (Fig 6) . The number of CFU-MKs (Fig 6C,D; 49Á3 AE 6Á4 vs. 59Á3 AE 6Á9; P = 0Á03), the percentages of CD41a + megakaryocytes (Fig 6E; 16Á8 AE 3Á3% vs. 18Á1 AE 3Á6%; P = 0Á04) and megakaryocyte polyploidy (N ≥ 4) ( Fig 6F; 7Á8 AE 2Á5% vs. 11Á4 AE 3Á1%; P = 0Á002) were increased after NAC treatment. Moreover, increased platelet production was observed in the NAC treatment group (Fig 6G; 970Á7 AE 209Á3 vs. 1612 AE 375Á2; P = 0Á006). The percentages of apoptotic megakaryocytes were similar in these three groups.
Evaluation of the clinical responses
To evaluate the efficacy and safety of oral NAC treatment (400 mg three times a day) in PT patients, we performed a pilot study including 10 PT patients. The complete response, response and overall response rates at 2 months after NAC treatment were 20% (2/10), 50% (5/10) and 70% (7/10), respectively. No apparent drug-associated side effects were observed in these patients. As indicated in Table SI , during NAC administration, no significant different CMV reactivation was observed between PT patients with complete response/response and no response groups (1/7 vs. 1/3; P = 0Á59). The platelet counts in PT patients who achieved complete response or response (N = 7) were significantly increased post-treatment when compared to pre-treatment (Fig 7A; 79 AE 19Á2 9 10 9 /l vs. 17 AE 2Á1 9 10 9 /l; P = 0Á002).
Discussion
In this prospective case-control study, we demonstrated for the first time that BM MSCs abnormalities, characterized by abnormal morphology, decreased proliferation, and higher levels of ROS and senescence, contribute to the pathogenesis of PT. Moreover, BM MSCs derived from PT patients exhibited quantitative and functional improvement following in vitro treatment with NAC, and these effects were mediated through down-regulation of both the p38 MAPK and p53 pathways. Although requiring further validation, the preliminary data of a pilot study showed that 7 of the enrolled 10 PT patients achieved overall response following NAC treatment without significant side effects.
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Prolonged isolated thrombocytopenia is a life-threatening complication that is frequently associated with severe haemorrhagic complications and poor outcome after allo-HSCT (Ramirez et al, 2011) . Although the exact pathogenesis of PT remains obscure, the increased peripheral platelet destruction and impaired megakaryocytopoiesis in BM have been reported to be related to the occurrence of PT (Yamazaki et al, 2006; Zhang et al, 2015a) . Our previous study showed reduced endothelial cells and dysregulated T cell responses in the BM microenvironment of PT patients, indicating that an impaired BM microenvironment might contribute to the occurrence of PT (Kong et al, 2014; Song et al, 2017) . Moreover, Zhang et al (2011) found that PT after allo-HSCT might be related to defects in megakaryocyte maturation, as a significantly increased percentage of immature megakaryocytes with low polyploidy was found in PT patients (Zhang Megakaryocytes ploidy distribution (F), the number of platelets released (G) and the apoptosis rate of megakaryocytes (H) were analysed. P-values <0Á05 were considered statistically significant. BFU-E, erythroid burst-forming units; CFU, colonyforming units; CFU-E, erythroid CFU; CFU-GEMM, mixed lineage CFU; CFU-GM, granulocyte-macrophage CFU; CFU-MK, megakaryocyte CFU; GGF, good graft function; HD, healthy donor; MK, megakaryocyte; NAC, N-acetyl-L-cysteine; PT, prolonged isolated thrombocytopenia.
[Colour figure can be viewed at wileyonlinelibrary.com] et al, 2011), which was associated with the recruitment of CD8 + T cells into BM (Zhang et al, 2015a ). In the current study, we found that the number of BM megakaryocytes in PT patients was lower than that in GGF patients. The CFU results further demonstrated that BM CD34 + cells of PT patients had a deficit in CFU-GEMM outgrowth compared with those from GGF patients and HD. Therefore, our data suggested that the process of megakaryocytopoiesis was impaired in PT patients. However, what drives the impaired megakaryocytopoiesis remains to be elucidated in PT patients.
As a critical component of the BM microenvironment, MSCs possess the capacity to support haematopoiesis and regulate immunological responses (Dazzi et al, 2006; Reems et al, 2010; Gebler et al, 2012) . Moreover, MSCs were reported to play important roles in regulating megakaryocytopoiesis. Cheng et al (2000) showed that BM MSCs could dramatically enhance megakaryocytes differentiation and platelet formation in vitro, and a more recent study confirmed that MSCs/megakaryocyte interactions play an important role in an advanced stage of megakaryocyte development using a coculture system (Pallotta et al, 2009) . Using a non-obese diabetic-severe combined immunodeficent mice transplantation assay, Angelopoulou et al (2003) showed co-transplantation of human BM MSCs with CD34 + HSCs enhances megakaryocytopoiesis, which was demonstrated by an increase in both BM CFU-MKs and circulating human platelets. However, no previous study has focused on the number and functional characterization of BM MSCs in PT patients following allo-HSCT. Moreover, whether the impaired BM MSCs influence megakaryocytopoiesis in PT patients has not been investigated. Similar to PT, immune thrombocytopenia (ITP) is also characterized by low platelet counts and immature megakaryocytes. Zhang et al (2016) reported that BM MSCs from ITP patients exhibited increased levels of apoptosis and senescence compared with healthy controls. However, we observed significantly increased levels of senescence and slightly higher levels of apoptosis in MSCs from PT patients compared with GGF patients, which indicated different mechanisms may contribute to the impaired MSCs in patients with PT or ITP. In the current study, we found that BM MSCs were quantitatively and functionally impaired in PT patients. Therefore, therapeutic strategies to improve the prognosis of PT patients by enhancing the number and function of BM MSCs are urgently needed.
Reactive oxygen species can regulate cell cycle progression, cell motility and growth factor signalling in many cell types, such as HSCs, endothelial cells and MSCs (Borodkina et al, 2014; Kong et al, 2016a; Shi et al, 2016) . Borodkina et al (2014) . showed that both the p53/p21 and p38 MAPK pathways are responsible for the aberrant ROS induced MSCs senescence in vitro. Li et al (2012) reported that the enhanced apoptosis and senescence of BM MSCs due to the higher intracellular ROS levels were associated with the activation of PI3K/Akt/FoxO3 in patients with systemic lupus erythematosus. In the current study, we found that the dysfunction of BM MSCs from PT patients was related to the higher ROS levels and the activation of the p38 MAPK pathway and p53 pathway. In contrast, no significant differences were detected in phospho-JNK, ERK or Akt levels between patients with PT and GGF.
N-acetyl-L-cysteine has been widely used as an antioxidant in many clinical studies, especially in respiratory diseases (Rushworth & Megson, 2014) . In this study, the impaired BM MSCs derived from PT patients were quantitatively and functionally improved by NAC in vitro. Therefore, NAC, as an antioxidant, appears to be a promising therapeutic strategy to optimize the BM microenvironment in PT patients. Indeed, our CFU results demonstrated that NAC could improve the ability of the impaired BM MSCs derived from PT patients to support haematopoietic progenitors to differentiate into megakaryocytes, as determined by the percentage of megakaryocytes and CFU-MKs plating efficiency in vitro. Moreover, our preliminary data, based on a pilot study including 10 PT patients, indicate that NAC might be a potential therapeutic approach for PT patients after allo-HSCT. In view of the relatively small numbers of PT patients studied, further prospective largescale randomized clinical trials are needed to validate our preliminary findings.
We are aware, however, that the pathogenesis of PT is heterogeneous. It would be interesting to further investigate whether the impaired BM MSCs directly affect megakaryocytopoiesis or act through their immunoregulatory effects in the occurrence of PT. Moreover, further studies are needed to determine the sources and regulation of abnormal intracellular ROS in BM MSCs from PT patients.
In summary, our data suggest that reduced and dysfunctional BM MSCs play a role in the pathogenesis of PT and that treatment with NAC could improve the impaired BM MSCs through down-regulation of the p38 MAPK and p53 pathways; these recovered BM-derived endothelial progenitor cells could support megakaryocytopoiesis. Moreover, our experimental and clinical data indicate that it would be of value to determine whether prophylactic or therapeutic application of antioxidant drugs can benefit PT patients after allo-HSCT based on large-scale clinical trials in the future.
